Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autologous Peripheral Nerve Tissue Grafts Implanted into the Nucleus Basalis of Meynert and Substantia Nigra at the Time of Bilateral Deep Brain Stimulation in Parkinson Disease: A Report of 2 Cases.

Neurosurgery practice·2025
Same author

Automated Imaging Differentiation for Parkinsonism.

JAMA neurology·2025
Same author

Two-year feasibility and safety of open-label autologous peripheral nerve tissue implantation during deep brain stimulation in patients with Parkinson's disease.

Journal of Parkinson's disease·2025
Same author

Recipient Reaction and Composition of Autologous Sural Nerve Tissue Grafts into the Human Brain.

Journal of clinical medicine·2023
Same author

Visualization of the Movement Disorder Society Unified Parkinson's Disease Rating Scale Results.

Journal of Parkinson's disease·2023
Same author

Direct delivery of an investigational cell therapy in patients with Parkinson's disease: an interim analysis of feasibility and safety of an open-label study using DBS-Plus clinical trial design.

BMJ neurology open·2022
Same journal

Social Determinants of Health and Their Association With Parkinson's Disease Prevalence in US Adults: Insights From NHANES 2001-2020.

Behavioural neurology·2026
Same journal

GLP-1 Agonist Attenuates Nicotine Reward-Related Behavior by Regulating the Prepro-Orexin in the Hypothalamus and Prepro-Glucagon in the Nucleus Tractus Solitarius.

Behavioural neurology·2026
Same journal

Using Virtual Reality to Complement Paper-and-Pencil Tests to Assess Visual Unilateral Spatial Neglect: A Feasibility Study.

Behavioural neurology·2026
Same journal

Adverse Childhood Experiences Underlie Race-Related Differences in Neural Reactivity to Stress.

Behavioural neurology·2026
Same journal

The Clinical Effect of Annonaceae Fruit Consumption on Caribbean Parkinson's Disease Severity.

Behavioural neurology·2026
Same journal

Mind the Gap: A Systematic Review of Borderline Intellectual Functioning in Childhood and Adolescence.

Behavioural neurology·2026
See all related articles

Related Experiment Video

Updated: May 29, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Emotional dysfunction in Parkinson's disease.

Lee X Blonder1, John T Slevin

  • 1Sanders-Brown Center on Aging and Departments of Behavioral Science and Neurology, University of Kentucky College of Medicine, Lexington, USA. lxblond@email.uky.edu

Behavioural Neurology
|August 31, 2011
PubMed
Summary
This summary is machine-generated.

Idiopathic Parkinson's disease (PD) often involves emotional dysfunction, including depression, anxiety, and apathy. Research suggests mesolimbic dopaminergic pathway abnormalities and serotonin-dopamine interactions are key to understanding and treating these mood disorders in PD patients.

More Related Videos

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Related Experiment Videos

Last Updated: May 29, 2026

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
07:26

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease
10:28

Dynamic Digital Biomarkers of Motor and Cognitive Function in Parkinson's Disease

Published on: July 24, 2019

Area of Science:

  • Neuroscience
  • Psychiatry
  • Neurology

Background:

  • Idiopathic Parkinson's disease (PD) presents with motor symptoms and significant emotional dysfunction.
  • Depression, anxiety, and apathy are common psychiatric comorbidities in PD patients, affecting 30-40% of individuals.
  • Understanding these non-motor symptoms is crucial for comprehensive PD patient care.

Purpose of the Study:

  • To review the neuropsychiatric abnormalities associated with Parkinson's disease.
  • To explore the neuropsychological, neuropharmacologic, and neuroimaging correlates of emotional dysfunction in PD.
  • To highlight the role of dopaminergic and serotonergic systems in mood disorders within PD.

Main Methods:

  • Review of existing neuropsychological and neuroimaging studies.
  • Analysis of neuropharmacological evidence related to mood regulation in PD.
  • Synthesis of data on dopaminergic and serotonergic pathway involvement.

Main Results:

  • Neuropsychological and neuroimaging studies indicate abnormalities in mesolimbic and mesocortical dopaminergic pathways in PD patients with emotional dysfunction.
  • Evidence suggests a critical interaction between serotonin and dopamine systems in the pathophysiology and treatment of mood disorders in PD.
  • These findings underscore the complex interplay of neurochemical systems in PD-related psychiatric symptoms.

Conclusions:

  • Neuropsychiatric symptoms, particularly mood disorders, are integral to the idiopathic Parkinson's disease experience.
  • Dopaminergic and serotonergic systems are key targets for understanding and managing emotional dysfunction in PD.
  • Further research into these neurochemical interactions can inform novel therapeutic strategies for Parkinson's disease.